ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Active, not recruiting
Acerta Pharma BV
Phase 1/Phase 2
2014-01-30
This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk)
inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma (SLL)
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Active, not recruiting
Acerta Pharma BV
Phase 1
2014-08-07
To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory
de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Active, not recruiting
Acerta Pharma BV
Phase 1
2014-08-18
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and
ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Recruiting
Acerta Pharma, LLC
Phase 1/Phase 2
2015-02-01
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with
rituximab in subjects with R/R FL.
Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab
in subjects with R/R MZL, as measured by ORR.
Part 3: To characterize the safety of acalabrutinib in combination with rituximab and
lenalidomide in subjects with R/R FL
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
